Delving Into the Patterns of Patient Engagement and Trends in Participation Within Recurrent Ovarian Cancer Clinical Trials
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Recurrent Ovarian Cancer
- Sponsor
- Power Life Sciences Inc.
- Enrollment
- 500
- Locations
- 1
- Primary Endpoint
- Number of patients who decide to participate in a recurrent ovarian cancer clinical trial
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
Clinical trials, with a particular focus on recurrent ovarian cancer, play a crucial role in assessing the safety and efficacy of novel treatments for this condition. These trials serve as essential tools to determine whether new medications outperform traditional therapies, providing substantial evidence to support their widespread adoption.
By actively participating in recurrent ovarian cancer observational study serves pivotal role in expanding the boundaries of medical knowledge and advancing the quality of care provided to those enduring the same condition.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Aged ≥ 18 years old
- •Able to comprehend the investigational nature of the protocol and provide informed consent
- •Diagnosis of recurrent ovarian cancer
Exclusion Criteria
- •No diagnosis of recurrent ovarian cancer confirmed
- •Inability to perform regular electronic reporting
- •Patient does not understand, sign, and return consent form
Outcomes
Primary Outcomes
Number of patients who decide to participate in a recurrent ovarian cancer clinical trial
Time Frame: 3 months
Rate of patients who remain in recurrent ovarian cancer clinical research to trial completion
Time Frame: 12 months